Nektar Therapeutics

NEKTAR THERAPEUTICS

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Nektar_Sign-San_Francisco-1

Analyst Color

Biotech

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

NKTR

REGN

Nektar&#39;s rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Konskie,,Poland,-,March,03,,2025:,Aerovironment,Company,Logo,Displayed

Earnings

Markets

AVAV

BMBL

CHYM

LIMN

NNNN

SMCI

TIGR

TTMI

AeroVironment Posts Better-Than-Expected Earnings, Joins QuantumScape, Bumble, BlackBerry And Other Big Stocks Moving Higher On Wednesday

Equities

Eurozone

Commodities

Intraday Update

ARRY

HUSA

ONMD

Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1

Press Releases

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Nektar Therapeutics Reports First Quarter 2025 Financial Results

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

ALT5 Sigma

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Maze Therapeutics

MBX Biosciences

Omeros

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

scPharmaceuticals

SNDL

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Tilray Brands

Tvardi Therapeutics

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

HC Wainwright & Co.

Jefferies

Oppenheimer

B. Riley Securities

Piper Sandler

Comments

Nektar Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell